Calgary, Alberta–(Newsfile Corp. – January 21, 2022) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it has signed a Global Master Services Agreement with My Next Health ("MNH"), and has, subject to TSXV approval, obtained a subscription from My Next Health in the amount of USD $150,000 at CAD $0.25 per Unit.
My Next Health Inc. ("MNH") is the world's leading patient-based AI-functional genomic medical analysis company. MNH is improving human health and accelerating the world's transition to precision medicine. From completing more than 10,000 in-person patient assessments (hands-on functional medicine and genome-based patient assessments) and from its comparison of that database to 60 million patient records, MNH has created the world's first functional genomic AI-based tool that delivers precision medical care, significantly improving an individual's health recommendations and clinical trial outcomes. MNH algorithms significantly impact clinical trial subject selection.
Hemostemix will incorporate MNH's functional genomic assays to complete an assay report by individual. Such analyses will enable Hemostemix to recruit subjects into its clinical trials who are best suited to achieve both the safety and efficacy results desired from a randomized double blind placebo controlled clinical trial.
"We are pleased to partner with Hemostemix and contribute our proprietary AI-based genomic and phenotypic tools, to enhance their ground-breaking personalized stem cell therapeutics. This collaboration exemplifies the power and precision of personalized autologous medicine," stated Dr. Richard Heinzl, CEO, MNH.
"MNH's tools and analyses enables Hemostemix to explain when, how and why ACP works. These innovations improve the underpinnings of our therapeutics markets, and significantly de-risks our clinical trials going forward," stated Thomas Smeenk, CEO.
ABOUT MY NEXT HEALTH
My Next Health Inc. ("MNH") is the world's leading patient focused, AI-functional-medicine-based genomic medical analysis company. MNH is improving human health and accelerating the world's transition to precision medicine. From completing more than 10,000 in-person patient assessments (hands-on functional medicine and genome-based patient assessments) and from its comparison of that database to 60 million patient records, MNH has created the world's first functional genomic AI-based tool that delivers precision medical care, significantly improving an individual's health recommendations and clinical trial outcomes. MNH algorithms will significantly impact clinical trial subject selection.
ABOUT HEMOSTEMIX
Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy and Dilated Cardiomyopathy. ACP-01 has been used to treat over 300 patients. ACP-01 is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.
On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.
The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit www.hemostemix.com.
For further information, please contact:
Contact: Thomas Smeenk, President, CEO & Co-Founder
TSmeenk@Hemostemix.com 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the use of AI based genomic assays that may impact the commercialization of ACP-01, with or in combination with other analytics. ‎‎There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies as well as management's ‎expectations of anticipated results; Hemostemix's general and administrative costs remaining constant; the receipt of all required regulatory ‎approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the ‎economy generally; consumer ‎interest in Hemostemix's services and products; competition and ‎Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to ‎fund Hemostemix's operations including any research, trials or studies, and the Litigation. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete its current CLI clinical trial, complete a satisfactory analyses and the results of such analyses and future clinical ‎trials; ‎litigation and potential litigation that Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation ‎affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete;‎ lack of qualified, skilled labour or loss of key individuals; and risks ‎related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to ‎try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, ‎service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and ‎financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a ‎possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix ‎offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/111105
On Wednesday, the Biden administration announced that it will make 400 million N95 face masks available free of charge to Americans. Here's how to get yours.
Dr. Owais Durrani, Emergency Medicine Physician, joins Yahoo Finance Live to discuss including the booster shot in definitions of being fully vaccinated, monitoring and testing for potential COVID symptoms, transmissibility in hospitals for non-COVID patients, and the outlook on variant case numbers.
There was no shortage of market-moving headlines in Thursday’s session: Netflix’s subscriber growth outlook let down investors, while battered tech stocks struggled to claw their way out of correction territory.
White House advisor Anthony Fauci said U.S. officials could authorize Pfizer and BioNTech's Covid vaccine for children younger than 5 next month.
The clinical-stage biotech company is working on an antiviral treatment to fight multiple variants of COVID-19.
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.
The CDC now recommends wearing respirators. Here are the best N95 masks and KN95 masks to buy online now to protect against Omicron COVID-19.
Shares of Novocure Limited (NASDAQ: NVCR) are jumping 12.9% higher as of 11:09 a.m. ET on Thursday. The solid gain came after investment firm Truist Financial upgraded the stock from a hold to a buy recommendation. Truist kept its 12-month price target for the stock at $125, which represents upside potential of more than 70%.
On a disappointing day for stock market investors — one in which a hopeful morning rally turned into another afternoon crash — marijuana investors are even more pessimistic than most. Turns out, he may not legalize marijuana after all. Marijuana legalization, if you recall, was a centerpiece of the Biden-Harris campaign platform in late 2020.
Starting next week, the US Government will make 400 million N95 masks available to the public for free. The masks will be sent to thousands of pharmacies and community health centers across the country where you can pick up a maximum of three masks per person.
Counterfeit N95 and KN95 masks are flooding the market. Here's how to tell if a respirator is real or fake, and how to buy a NIOSH-approved mask.
(Bloomberg) — Elon Musk’s brain implant company Neuralink is now hiring a clinical trial director, an indication that the company’s longstanding goal of implanting chips in human brains is coming closer.Most Read from BloombergTech Leads Stocks to Worst Week Since March 2020: Markets WrapJeremy Grantham Doubles Down on Crash Call, Says Selloff Has StartedAmerican Airlines Sues The Points Guy Over Its Rewards Management AppCrypto Selloff Pushes Bitcoin to a Six-Month Low of $38,000Early Omicron
New studies point toward the effectiveness of a third dose of the vaccine in preventing hospitalizations from the new Omicron variant.
While the number of deaths soared, the infection rate dropped significantly along with the number of people hospitalized.
Massachusetts’ Department of Public Health on Thursday—for the first time—made a distinction between COVID-19 patients hospitalized with “primary” and “incidental" cases.
The Omicron variant is infecting thousands of people every day in the U.S., from first-time cases to breakthrough infections and reinfections. Virus experts have been advocating for booster shots as the fast-spreading variant continues to circulate, with boosters now being referred to as the "optimal protection" against Omicron. Copious studies have shown that protection from just one or two vaccine doses wanes significantly over time, and in the face of new COVID variants. Now, experts are deba
Though COVID-19 vaccines and boosters provide strong protection against severe disease, hospitalizations, and deaths, the quickly-spreading Omicron variant remains a significant challenge.
You can sign up for your four free at-home COVID-19 rapid tests starting today. Here's how, plus more FDA-approved options.
The controversial drug used to kill parasites has shown promise with COVID-19, but definitive studies are lacking.
Use this interactive map to view the hospital bed occupancy percentages at local hospitals.

source